Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy: Molecular Therapy - Oncolytics

The next wave of cellular immunotherapies in pancreatic cancer - ScienceDirect

Coengineering specificity, safety, and function into T cells for cancer immunotherapy - Giordano Attianese - 2023 - Immunological Reviews - Wiley Online Library

CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

Frontiers The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies

Current applications and future perspective of CRISPR/Cas9 gene editing in cancer, Molecular Cancer

Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy, Molecular Cancer

PDF) Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy

Adoptive Cellular Therapy for Solid Tumors American Society of Clinical Oncology Educational Book

Immuno, Free Full-Text

Full article: Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management

Frontiers CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma

Frontiers Emerging Strategies in TCR-Engineered T Cells

CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients

Promises and challenges of adoptive T-cell therapies for solid tumours